REG - Oxford Biomedica PLC - Repayment of Debt Facility

Oxford BioMedicaAnnouncement

28/06/2019 07:05

RNS Number : 7435D
Oxford Biomedica PLC
28 June 2019
 


 
 
 
Oxford Biomedica
 
Repayment of Debt Facility
 
 
Oxford, UK - 28 June 2019: Oxford Biomedica plc (LSE:OXB) ("OXB" or "the Group"), a leading gene and cell therapy group, announces that, further to the announcement of 28 May in relation to Novo Holdings' strategic investment in the Group and, in accordance with the stated use of proceeds from the transaction, Oxford Biomedica has now repaid in full its debt facility with Oaktree Capital Management.
 
 
-Ends-
 



Enquiries:


 




 
Oxford Biomedica plc
 
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development & IR
Sarah MacLeod, Head of Communications
 


 
 
 
T: +44 (0)1865 783 000
T: +44 (0)1865 783 000
T: +44 (0)1865 954 161 / E: ir@oxb.com
T: +44 (0)7747 602 739 / E: media@oxb.com




 
Consilium Strategic Communications
 
Mary-Jane Elliott/Matthew Neal


 
 
 
T: +44 (0)20 3709 5700



 
 
 
About Oxford Biomedica
 
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCDDGDLLDDBGCR